April 02, 2026. 40 items curated for clinical relevance.
Above Threshold
Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
Alabama’s medical cannabis program is preparing to begin sales in spring 2026, establishing a new treatment option for licensed clinicians to recommend to qualified patients in the state.
Read more →Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
Cannabinoids CBD and CBG show potential therapeutic effects against hepatic steatosis, offering cannabis clinicians evidence-based information for patient consultation regarding liver health applications.
Read more →From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
The article examines regulatory enforcement actions against cannabis beverage companies, highlighting compliance challenges clinicians must consider when advising patients about commercial cannabis products.
Read more →Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …
Cannabinoids CBD and CBG demonstrate potential therapeutic effects on hepatic steatosis, relevant for clinicians evaluating cannabis applications in metabolic and liver disease management.
Read more →New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …
I’m unable to complete this task as the article summary is missing. Please provide the full summary text so I can write an accurate, factual sentence for cannabis clinicians.
Read more →New Top Cannabis Regulator Sets Priorities In First Board Meeting
A newly appointed cannabis regulator outlined policy priorities in their initial board meeting, establishing regulatory direction relevant to clinical cannabis practice and patient care standards.
Read more →Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
Brazil’s evolving cannabis regulations present clinical practice implications that healthcare providers must understand to effectively navigate legal frameworks and patient care standards in this emerging market.
Read more →2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT
Two Cincinnati breweries are legally challenging Ohio’s prohibition on THC-infused beverages, relevant to clinicians prescribing cannabis products and understanding regulatory barriers to alternative consumption methods.
Read more →New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG
Ohio’s new law restricts retail distribution of THC-infused beverages, limiting clinician patient access to this cannabis delivery method and potentially affecting dosing recommendations.
Read more →Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo
Oregon lawmakers rejected legislation that would have limited THC concentrations in cannabis edibles, potentially affecting dosing standardization and patient safety considerations in clinical practice.
Read more →Attempt to limit potency of THC in marijuana edibles fails at Oregon Legislature
Oregon legislators failed to pass limits on THC potency in marijuana edibles, affecting dosing standardization and patient safety considerations for clinical cannabis practice.
Read more →Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health
Cannabis compounds CBD and CBG reduce hepatic steatosis and improve metabolic markers, potentially offering therapeutic options for managing fatty liver disease in clinical practice.
Read more →Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
This article examines formulation and fabrication approaches for delivering cannabinoids through oral mucosal tissues, addressing a clinically relevant alternative route to systemic absorption for cannabinoid therapeutics.
Read more →Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
CBD-dominant cannabis products demonstrate significant anxiety relief in clinical studies, providing evidence-based treatment options for clinicians managing anxiety disorders in patient populations.
Read more →Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
A clinical trial demonstrates cannabis extracts’ efficacy in reducing myofascial pain, providing clinicians evidence-based data for treating this common musculoskeletal condition.
Read more →As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely
This article examines a Supreme Court case relevant to medical cannabis patients and likely addresses legal or regulatory issues affecting clinical cannabis practice and patient access.
Read more →The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra
Unable to provide summary: article content not provided, only title and source metadata available.
Read more →Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch
Marijuana gummies sold in Ohio were recalled, requiring clinicians to be aware of potential product safety issues and advise patients about affected batches.
Read more →New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire
A new organization is forming in advance of Medicare-funded CBD pilot programs, which could expand clinical research opportunities and insurance coverage pathways for cannabis-based treatments.
Read more →Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA
This resource discusses legal prohibitions related to marijuana’s regulatory status, which matters because clinicians must understand jurisdictional regulations affecting patient recommendations and practice compliance.
Read more →Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries
A Louisiana legislator has proposed legalizing recreational marijuana sales through licensed dispensaries, which matters to clinicians as it could expand patient access while creating regulatory frameworks affecting medical cannabis practices.
Read more →Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
A Georgia mother’s homemade medical cannabis formulation has entered commercial dispensary distribution, demonstrating patient-developed recipes gaining regulatory approval and clinical accessibility.
Read more →Ohio THC drink ban draws lawsuit from Cincinnati breweries
Ohio’s THC beverage ban prompted legal challenges from breweries, affecting regulatory frameworks that cannabis clinicians must understand when counseling patients about legal product availability.
Read more →Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
Israeli researchers identified cannabis compounds as potential therapeutic agents for fatty liver disease, offering clinicians a novel treatment avenue for a prevalent hepatic condition currently lacking approved pharmacological options.
Read more →Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog
Virginia’s adult-use cannabis sales legislation passed both legislative chambers and requires reconciliation of different versions before becoming law, representing regulatory progress relevant to clinical practice standards.
Read more →Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
A Tennessee study examines medical marijuana’s therapeutic benefits and risks, relevant as the state’s regulatory status remains uncertain for clinical practice.
Read more →2026 Utah legislature on cannabis, psychedelics and kratom – Fox 13
The 2026 Utah legislature will address cannabis, psychedelics, and kratom policy—matters relevant to clinicians prescribing cannabis in states considering regulatory changes.
Read more →Oregon Bill To Ban Marijuana Edibles With More Than 10 Milligrams Of THC Fails
Oregon’s failed bill would have restricted THC edible potency to 10mg per serving, directly affecting patient dosing options and clinical cannabis recommendations in the state.
Read more →Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube
Georgia proposed legislation would restrict police use of cannabis/hemp odor as probable cause for searches, affecting law enforcement procedures and patient legal protections.
Read more →Study reveals cannabis compounds reduce threat of fatty liver disease | Health
Cannabis compounds show potential to reduce fatty liver disease risk, offering clinicians evidence-based information for patient discussions about cannabinoid therapeutic applications and metabolic health outcomes.
Read more →Prescription Cannabidiol CBD Oil Market to Hit US$ 190.9 Billion by 2032 at 23.48% CAGR
Prescription CBD oil market projected to reach $190.9 billion by 2032 with 23.48% annual growth, indicating significant expansion of cannabinoid therapeutics in clinical practice.
Read more →InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non …
InMed Pharmaceuticals discontinued its non-therapeutic cannabis operations through BayMedica, refocusing entirely on pharmaceutical drug development—relevant to clinicians monitoring cannabinoid-derived medication advancement.
Read more →Cannabis Extracts Significantly Reduce Myofascial Pain | Trending – Labroots
Cannabis extracts show efficacy in reducing myofascial pain, providing clinicians with evidence-based information for patient treatment planning and dosing recommendations in pain management.
Read more →Pediatricians warn about cannabis use disorder, kids’ easy access to the drug – YouTube
Pediatricians highlight cannabis use disorder in children and accessibility concerns, providing clinicians evidence-based warnings about youth-focused clinical considerations and public health implications.
Read more →West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …
West Virginia legislators approved allocating medical marijuana tax revenue, establishing financial frameworks that directly impact program funding, licensing infrastructure, and clinical service availability for practitioners.
Read more →Study highlights positive, negatives of medical marijuana – WKRN News 2
A news report examining research findings on medical marijuana’s therapeutic benefits and adverse effects, relevant for clinicians evaluating cannabis treatment efficacy and safety profiles.
Read more →The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News
This article examines roadside THC testing methods and insurance policies affecting impaired driving enforcement, relevant to clinicians assessing patient cannabis use and impairment.
Read more →Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
A Georgia mother’s homemade medical cannabis formulation has been commercialized and is now available through licensed dispensaries, representing consumer-developed products entering the regulated market.
Read more →‘Pot for Potholes Act’ aims to legalize marijuana in Tennessee and distribute taxes to repair …
Tennessee proposed legislation would legalize marijuana and allocate tax revenue to infrastructure, affecting patient access, clinical practice scope, and regulatory frameworks for healthcare providers.
Read more →Digest-Level Clinical Commentary
The convergence of emerging preclinical data on cannabinoid hepatoprotection, expanding regulatory frameworks across multiple states, and growing clinical evidence for anxiety and pain management suggests that cannabis medicine is transitioning from anecdotal practice toward condition-specific applications with measurable outcomes. However, the persistent regulatory fragmentation around potency standards, beverage formulations, and delivery mechanisms indicates that clinical practitioners will need to navigate an increasingly complex landscape where evidence-based dosing protocols have not yet caught up with market availability. My practice must prioritize patient education on the gap between promising in vitro and animal studies on compounds like CBD and CBG versus the limited human clinical data, particularly regarding optimal dosing, drug interactions, and long-term safety in hepatic disease.
The digest reflects a growing body of preclinical and clinical evidence supporting cannabinoid-based therapeutics for metabolic and pain-related conditions, particularly CBD and CBG for hepatic steatosis and anxiety disorders. Simultaneously, regulatory frameworks across multiple jurisdictions are evolving in real time, with states implementing varied approaches to potency limits and product categories, creating a fragmented landscape that complicates clinical standardization and patient access. This tension between emerging therapeutic promise and regulatory heterogeneity suggests the field is transitioning from prohibition toward evidence-informed policy, though significant gaps remain in dosing standardization, long-term safety data, and clinical trial infrastructure.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: